Rituximab treatment for lupus nephritis: A systematic review.
2020
Purpose: We used the Cochrane systematic review to analyze the effectiveness
and safety of rituximab for lupus nephritis.
Methods: Systematic search was performed among Cochrane clinical
controlled trials database, MEDLINE, MEDLINE-IN-Process and Other
Non-Indexed Citations, EMBASE, EBSCO CINAHL, CNKI, VIP and
Wanfang database from the establishment of the database to February 2016.
The effectiveness and safety were evaluated in terms of the complete remission
rate, total remission rate, urinary protein, Systemic Lupus Erythematosus
Disease Activity Index changes and adverse events rate. Data were analyzed by
the Review Manager Software version 5.3.
Results: Five RCTs that met the inclusion criteria, including a total of 238
patients, were enrolled in our study. The results showed that the complete
remission rate in rituximab group was a significantly higher than that of
cyclophosphamide group. The difference between the two groups was
statistically significant (OR=2.80, 95%CI(1.08,7.26), P=0.03). But there was no
significant difference between the two groups in partial and total remission rate.
The complete remission rate, partial remission rate and total remission rate in
rituximab treatment group was similar compared with mycophenolate mofetil
group and rituximab combined with cyclophosphamide group. The adverse
reaction rate was also similar among the groups.
Conclusion: The study systematically analyzed the effectiveness and safety of
rituximab for lupus nephritis, which suggested that the complete remission rate
of rituximab in the treatment of lupus nephritis was a significantly higher than
that of cyclophosphamide group, while the effectiveness and safety was of no
difference compared with cyclophosphamide and mycophenolate mofetil.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
5
References
1
Citations
NaN
KQI